Intercept Pharma

Intercept's liver med Ocaliva takes heat at FDA expert meeting, as hopes for full approval dim
Fierce Pharma
Mon, 09/16/24 - 10:54 am
Intercept Pharma
Ocaliva
FDA
primary biliary cholangitis
US FDA staff questions confirmatory trial data for Intercept's liver disease drug
Reuters
Wed, 09/11/24 - 11:51 am
FDA
Intercept Pharma
Ocaliva
clinical trials
primary biliary cholangitis
liver disease
Ipsen, eyeing approval, reveals mixed liver disease data on challenger to Intercept and CymaBay
Fierce Biotech
Tue, 11/14/23 - 09:20 am
Ipsen
Genfit
elafibranor
liver disease
Intercept Pharma
CymaBay Therapeutics
Alfasigma To Acquire Intercept Pharma For $19 Per Share In Cash
RTT News
Tue, 09/26/23 - 10:13 am
Intercept Pharma
M&A
Alfasigma
NASH
Demise of Intercept’s NASH Program Highlights Safety Hurdles Facing the Space
BioSpace
Mon, 07/31/23 - 10:18 am
Intercept Pharma
NASH
obeticholic acid
Intercept restructures as Ocaliva's NASH hopes dashed again with FDA rejection
Fierce Pharma
Thu, 06/22/23 - 10:46 pm
Intercept Pharma
NASH
Ocaliva
obeticholic acid
FDA
Future of Intercept’s NASH drug in doubt after FDA panel rejection
BioPharma Dive
Sun, 05/21/23 - 10:51 pm
Intercept Pharma
FDA
NASH
obeticholic acid
FDA staff unsure NASH drug’s ‘modest’ benefits outweigh safety risks
BioPharma Dive
Wed, 05/17/23 - 10:57 pm
FDA
NASH
OCA
obeticholic acid
Intercept Pharma
FDA schedules adcomms for Entasis' antimicrobial treatment, Intercept's NASH hopeful
Endpoints
Mon, 03/13/23 - 10:19 am
FDA
Entasis
Intercept Pharma
sulbactam-durlobactam
obeticholic acid
NASH
FDA accepts Intercept’s resubmitted NDA for obeticholic acid
Clinical Trials Arena
Thu, 01/26/23 - 10:51 am
FDA
Intercept Pharma
OCA
obeticholic acid
NASH
NASH: Wall Street’s Forgotten Mega Blockbuster Indication
BioSpace
Mon, 12/12/22 - 10:13 am
NASH
Intercept Pharma
Novo Nordisk
Madrigal Pharmaceuticals
Inventiva
Galmed Pharmaceuticals
Ocaliva fails NASH trial just as Intercept charts path toward FDA application
Fierce Pharma
Fri, 09/30/22 - 12:31 pm
Intercept Pharma
NASH
obeticholic acid
Ocaliva
clinical trials
FDA
Two years after CRL, Intercept will meet with FDA later this month to discuss new analysis of NASH drug
Endpoints
Thu, 07/7/22 - 10:28 am
Intercept Pharma
OCA
obeticholic acid
FDA
NASH
Key data catalysts for the industry’s small players
EP Vantage
Fri, 07/1/22 - 09:35 am
Intercept Pharma
Akero
NASH
Kymera
atopic dermatitis
Zealand Pharma
short bowel syndrome
Relmada
Verona
Anavex
Assembly Biosciences
Aldeyra
Intercept sells international rights to liver drug in $400M deal
BioPharma Dive
Thu, 05/5/22 - 11:23 pm
Intercept Pharma
Advanz Pharma
Ocaliva
liver disease
3 Biotech Stocks With Major Catalysts in January
Motley Fool
Tue, 01/4/22 - 10:25 am
Novavax
vaccines
COVID-19
FDA
Intercept Pharma
Ocaliva
NASH
Madrigal Pharmaceuticals
resmetirom
10 clinical trials to watch in the first half of 2022
BioPharma Dive
Mon, 01/3/22 - 10:46 am
clinical trials
Pfizer
Arena Pharmaceuticals
etrasimod
Sanofi
GSK
vaccines
COVID-19
Roche
gantenerumab
AbbVie
Gilead Sciences
Trodelvy
Karuna Therapeutics
KarXT
Intercept Pharma
obeticholic acid
Allogene
ALLO-501a
Intercept, awaiting needed trial data, pulls its NASH drug application in Europe
BioPharma Dive
Fri, 12/10/21 - 12:00 am
Intercept Pharma
NASH
Europe
obeticholic acid
FDA adds new 'do not use' note to Intercept's Ocaliva label after a slew of side effect reports in cirrhosis patients
Endpoints
Thu, 05/27/21 - 11:06 am
Intercept Pharma
NASH
Ocaliva
FDA
primary biliary cholangitis
Intercept shakeup continues as CMO, former NASH chief resigns. Is the NASH biotech abandoning its flagship disease?
Endpoints
Tue, 02/23/21 - 11:14 pm
Intercept Pharma
NASH

Pages